SCHEMBL4703063

SCHEMBL4703063

CCC(=O)c1ccc2c(c1)CN(CCCSc1nnc(-c3cccnc3)n1C)C2

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
RAB9A P51151 1/20 0.53
DRD3 P35462 10/20 0.52
KCNH2 Q12809 5/20 0.52
POLB P06746 2/20 0.51
LMNA P02545 1/20 0.51
DRD2 P14416 9/20 0.51
TSHR P16473 1/20 0.49
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PPARG P37231 1/20 0.47
KMT2A Q03164 1/20 0.47
NR2E3 Q9Y5X4 1/20 0.47
NCOR2 Q9Y618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702577 0.90 ALDH1A1 (0.57) ALDH1A1RAB9ADRD3KCNH2POLB
Hydrochloric Acid SCHEMBL4861989 0.89 ALDH1A1 (0.56) ALDH1A1RAB9ADRD3KCNH2POLB
SCHEMBL4703079 0.85 DRD3 (0.59) ALDH1A1RAB9ADRD3KCNH2POLB
SCHEMBL4701185 0.83 DRD3 (0.57) ALDH1A1DRD3KCNH2POLBDRD2
SCHEMBL4702317 0.83 DRD3 (0.56) ALDH1A1RAB9ADRD3KCNH2DRD2
SCHEMBL4705751 0.82 ALDH1A1 (0.41) ALDH1A1RAB9ADRD3KCNH2POLB
Hydrochloric Acid SCHEMBL4872657 0.81 ALDH1A1 (0.41) ALDH1A1DRD3KCNH2POLBLMNA
SCHEMBL4702554 0.80 DRD3 (0.54) ALDH1A1RAB9ADRD3KCNH2DRD2
SCHEMBL4704579 0.77 DRD3 (0.59) ALDH1A1RAB9ADRD3KCNH2DRD2
Hydrochloric Acid SCHEMBL7202732 0.77 DRD3 (0.64) DRD3KCNH2DRD2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465744-B2 Triazole compounds and the therapeutic use thereof ABBOTT GMBH & CO. KG (DE) 2008-12-16 US disclosed
EP-1594861-B1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF ABBOTT GMBH & CO KG (DE) 2008-06-18 EP disclosed
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2006-10-26 US disclosed
EP-1594861-A1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF Abbott GmbH & Co. KG (DE) 2005-11-16 EP disclosed
WO-2004069830-A1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF ABBOTT GMBH & CO. KG (DE) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline DRD3, SLC6A3, ADORA3 ALDH1A1 1075/4885RAB9A 3232/4885DRD3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.